2026-27 COVID vaccine strain selection; low uptake persists

FDA meeting Thursday to pick 2026-27 COVID strain (XFG vs NB.1.8.1) despite WHO recommending LP.8.1. XFG is now dominant and more immune-evasive. Low adult uptake (17.5%) remains concern. Protein-based COVID vaccine shows superior tolerability in new study, offering alternative for boosters. Makary departure adds uncertainty to FDA vaccine decisions.